Education
About Us
Working with TipRanks
Follow Us
Medicamen Biotech Limited (IN:MEDICAMEQ)
:MEDICAMEQ
Total Valuation
Medicamen Biotech Limited has a market cap or net worth of ₹3.70B. The enterprise value is ₹3.65B.
Market Cap₹3.70B
Enterprise Value₹3.65B
Share Statistics
Medicamen Biotech Limited has 13,562,815 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,562,815
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Medicamen Biotech Limited’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 1.82%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)1.82%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee4.30M
Profits Per Employee188.05K
Employee Count378
Asset Turnover0.55
Inventory Turnover1.99
Valuation Ratios
The current PE Ratio of Medicamen Biotech Limited is 56.5. Medicamen Biotech Limited’s PEG ratio is -2.50.
PE Ratio56.5
PS Ratio3.86
PB Ratio2.95
Price to Fair Value2.95
Price to FCF-52.55
Price to Operating Cash Flow-29.81
PEG Ratio-2.50
Income Statement
In the last 12 months, Medicamen Biotech Limited had revenue of 1.63B and earned 71.08M in profits. Earnings per share was 5.59.
Revenue1.63B
Gross Profit389.90M
Operating Income67.92M
Pretax Income98.80M
Net Income71.08M
EBITDA201.02M
Earnings Per Share (EPS)5.59
Cash Flow
In the last 12 months, operating cash flow was -124.06M and capital expenditures -21.75M, giving a free cash flow of -145.81M billion.
Operating Cash Flow-124.06M
Free Cash Flow-145.81M
Free Cash Flow per Share-10.75
Dividends & Yields
Medicamen Biotech Limited pays an annual dividend of ₹1, resulting in a dividend yield of 0.26%
Dividend Per Share₹1
Dividend Yield0.26%
Payout Ratio12.20%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.60
52-Week Price Change-32.09%
50-Day Moving Average339.55
200-Day Moving Average366.39
Relative Strength Index (RSI)28.00
Average Volume (3m)2.40K
Important Dates
Medicamen Biotech Limited upcoming earnings date is Jun 3, 2026, TBA (Confirmed).
Last Earnings DateFeb 13, 2026
Next Earnings DateJun 3, 2026
Ex-Dividend Date―
Financial Position
Medicamen Biotech Limited as a current ratio of 2.11, with Debt / Equity ratio of 14.03%
Current Ratio2.11
Quick Ratio1.31
Debt to Market Cap0.05
Net Debt to EBITDA1.47
Interest Coverage Ratio2.15
Taxes
In the past 12 months, Medicamen Biotech Limited has paid 33.24M in taxes.
Income Tax33.24M
Effective Tax Rate0.34
Enterprise Valuation
Medicamen Biotech Limited EV to EBITDA ratio is 32.66, with an EV/FCF ratio of -55.02.
EV to Sales4.04
EV to EBITDA32.66
EV to Free Cash Flow-55.02
EV to Operating Cash Flow-66.59
Balance Sheet
Medicamen Biotech Limited has ₹436.79M in cash and marketable securities with ₹386.49M in debt, giving a net cash position of ₹50.31M billion.
Cash & Marketable Securities₹436.79M
Total Debt₹386.49M
Net Cash₹50.31M
Net Cash Per Share₹3.71
Tangible Book Value Per Share₹166.90
Margins
Gross margin is 32.17%, with operating margin of 4.18%, and net profit margin of 4.37%.
Gross Margin32.17%
Operating Margin4.18%
Pretax Margin6.08%
Net Profit Margin4.37%
EBITDA Margin12.37%
EBIT Margin8.02%
Analyst Forecast
The average price target for Medicamen Biotech Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-9.16%
EPS Growth Forecast49.09%